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Abstract
Background: Worldwide, over 500,000 people are diagnosed with head and neck cancer each year, a disease with
major impact on life expectancy and quality of life. The purpose of the Netherlands Quality of life and Biomedical
Cohort study (NET-QUBIC) is to advance interdisciplinary research that aims to optimize diagnosis, treatment, and
supportive care for head and neck cancer patients and their informal caregivers.
Methods: Using an extensive assessment protocol (electronic clinical record form, patient reported outcome measures and
fieldwork (interviews and physical tests)), clinical data and data on quality of life, demographic and personal factors,
psychosocial (depression, anxiety, fatigue, pain, sleep, mental adjustment to cancer, posttraumatic stress), physical (speech,
swallowing, oral function, malnutrition, physical fitness, neurocognitive function, sexual function), lifestyle (physical activity,
nutrition, smoking, alcohol, drugs), and social factors (social function, social support, work, health care use, and costs) are
collected and stored in the data warehouse. A longitudinal biobank is built with tumor tissue, blood and blood
components, saliva samples, and oral rinses. An infrastructure for fieldwork and laboratory protocols is established at all
participating centers. All patients fill out patient reported outcome measures before treatment and at 3, 6, 12, 24, 36, 48, and
60months follow-up. The interviews, physical tests and biological sample collection are at baseline and 6, 12, and 24months
follow-up. The protocol for caregivers includes blood sampling and oral rinses at baseline and a tailored list of
questionnaires, administered at the same time points as the patients. In total, 739 HNC patients and 262 informal caregivers
have been included in 5 out of the 8 HNC centers in the Netherlands.
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Discussion: By granting access to researchers to the NET-QUBIC data warehouse and biobank, we enable new research
lines in clinical (e.g. treatment optimization in elderly patients), biological (e.g. liquid biopsy analysis for relapse detection),
health related quality of life (e.g. the impact of toxicity on quality of life), and interrelated research (e.g. health related quality
of life in relation to biomarkers and survival).
Keywords: Head and neck cancer, Survival, Health related quality of life, Symptoms, Toxicity, Data warehouse, Biobank,
Cohort study, Caregivers
Background
Worldwide, more than half a million people per year
are diagnosed with head and neck cancer (HNC) [1],
a disease with major impact on the patient but also
on their partner, and family. In the Netherlands, al-
most all HNC patients are treated in specialized HNC
centers. HNC survival rates in the Netherlands are
more favorable compared those in other European
countries [2], which can in part be explained by this
centralization of treatment and care. However, there
is still room for improvement, not only with respect
to survival but also regarding symptom management
and health related quality of life (HRQOL) [3–5].
Previous research over the past decades provided
convincing evidence that cancer patients in general
have to deal with various physical, psychological, and
social side effects of cancer and cancer treatment,
negatively affecting HRQOL. In HNC patients, spe-
cific stressors as oral dysfunction (e.g. xerostomia)
and related swallowing and speech impairment and
malnutrition often lead to emotional distress as de-
pression and anxiety. This previous research also
showed considerable variation between patients: some
patients are at risk for poor HRQOL, while others are
protected [6–18]. Cancer does not only have a major
impact on HRQOL of HNC patients, but also on
HRQOL of their informal caregivers [19–28]. Limited
data exists on the supportive care needs of HNC pa-
tients and their caregivers, and these needs may de-
pend on the type of HNC and the time point of the
cancer illness trajectory [29–32]. In addition to the
impact on patients and caregivers, cancer may also
put burden on society. HNC patients have higher
medical care consumption and are more likely to be
unemployed than other cancer patients [33–38].
In HNC patients, associations between HRQOL and
survival have been found. Factors influencing survival
(e.g. age at time of diagnosis, tumor stage, metastasis,
and comorbidity) have impact on HRQOL. Additionally,
HRQOL has prognostic value for survival in HNC can-
cer patients, independently from known predictors as
sociodemographic and clinical parameters [39–52].
However, the association between HRQOL and survival
is complex. Empirical evidence suggests that tumor- and
patient-related biomarkers of endocrine, immune, and
autonomic (dys)function are associated with both
HRQOL and survival [53–58]. Biomarkers of neuroen-
docrinological and neuroimmunological function may
play a role in the association between HRQOL and sur-
vival. Neuroendocrinological markers include the activa-
tion of the HPA-axis resulting in increased secretion and
flattened circadian rhythm of cortisol, and specific hor-
mone levels may impact resistance mechanisms during
treatment. Neuroimmunological explanations include in-
creased immune responses and increased levels of pro-
inflammatory cytokines (interleukin (IL)-1, IL-6 and
TNF-a). Comprehensive insight in all these factors
assessed in a standardized manner in large study popula-
tions is necessary to unravel these complex associations.
Despite the existing body of evidence, there is also an
unmet need for better understanding of all aspects of
HRQOL in the context of increasing long-term survival
and growing attention for cancer survivorship [32, 59–61].
This paper describes a project that aims to collect longitu-
dinal data and answer some of these questions. In
addition, data is stored in a national data warehouse that
can be disseminated to other researchers. The longitudinal
design of the study enabled the longitudinal collection of
biological samples and storage in a biobank of this large
prospective cohort of HNC patients and their informal
caregivers. The study is indicated as the NETherlands
Quality of life and Biomedical Cohort study in head and
neck cancer (NET-QUBIC) (www.kubusproject.nl). In this
protocol paper, sociodemographic and clinical characteris-
tics of the study sample of 739 patients and 262 informal
caregivers are provided. Also, the key components of the
NET-QUBIC project are described: the study population
(including sample size calculation), the comprehensive
electronic case report form (eCRF), the extensive outcome
assessment protocol, biobanking protocols and quality
controls, data management (collection and storage), and
data and sample dissemination procedures (including legal
issues). This paper thus also facilitates other consortia
planning to set up a large prospective cohort study such
as NET-QUBIC.
Methods/design
Aim, design, and setting
The purpose of the Netherlands Quality of life and Bio-
medical Cohort study in HNC (NET-QUBIC) is to
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advance interdisciplinary research that aims to optimize diag-
nosis, treatment, and supportive care targeting HNC patients
and their informal caregivers. NET-QUBIC is designed as a
longitudinal observational cohort study. In parallel to the
data collection, is the establishment of a biobank.
Study population
Inclusion criteria in NET-QUBIC are: newly diagnosed
squamous cell carcinomas in the head and neck (oral
cavity, oropharynx, hypopharynx, larynx, unknown pri-
mary; all stages); age > 18 years; treatment with curative
intent; all treatment modalities (surgery, radiotherapy,
chemotherapy and combinations); able to write, read,
and speak Dutch. Exclusion criteria are: other tumors in
the head and neck (e.g. lymphoma, skin malignancies,
thyroid cancer); patients unable to understand the ques-
tions or test instructions; and severe psychiatric co-
morbidities (i.e. schizophrenia, Korsakoff ’s syndrome, se-
vere dementia), or unable to understand informed con-
sent. Eligible patients are treated according to the
current standard in the participating centers and that
have been defined in national guidelines on diagnosis,
treatment, and follow-up care. Via the patient, the
spouse or another family member or lay caregiver (infor-
mal caregiver) is asked to participate in this project.
Sample size calculation
The sample size calculation is based on the primary
research question, i.e. to describe the course of
HRQOL over time. We aim to detect a difference
over 60 months of 4 points change on the global
HRQOL scale of the European Organization for Re-
search and Treatment of Cancer (EORTC) quality of
life questionnaire QLQ-C30 between categories of
relevant variables (for example between patients with
and without depression), using a residual standard de-
viation of 10 points within categories, and using an α
of 0.05 and a power (β) of 0.80. For the dependency
of the 5 repeated measures in the study, we assume
an intraclass correlation coefficient of 0.50. This results in
a total sample size of 462. Taking into account study attri-
tion of 60% (35% dropout due to mortality and 25% due
to other causes), we aim to include 739 HNC patients. In
addition, informal caregivers when available during intake
will be included. Based on our previous research indicat-
ing that 70% of HNC patients have a caregiver and 50%
willing to participate, we expect to include 258 informal
caregivers.
Case report form
An electronic Case Report Form has been built (Open-
Clinica) and information is retrieved from medical re-
cords. Consensus was reached on the data items to be
collected, and changes during the study such as TNM8
impacted the data structure. General clinical information
as well as tumor characteristics, detailed treatment infor-
mation, and pathology data are collected by trained re-
searchers. General information includes incidence date,
age, sex, physical performance, performed diagnostics,
ACE-27 comorbidity score and weight loss prior to
treatment. Tumor characteristics include tumor subsite,
lateralization, stage, and lymph node metastasis, accord-
ing to the TNM7 and TNM8 classification, and in oro-
pharyngeal tumors HPV status and type of HPV test.
Information on treatment encompasses a question on
type of treatment, followed by more detailed questions
per treatment option.
For surgery, information on type of resection, recon-
struction, type of neck dissection (including details
about removed levels and nonlymphatic structures),
tumor-free margins, extended morphology of the tumor,
grade of differentiation, number of nodes removed,
number of tumor-positive nodes, extranodal spread.
For radiotherapy, information on type of radiotherapy
(primary, postoperative or other), technology use, boost
methods, and start and end date of radiotherapy is col-
lected. In addition, for patients treated with primary de-
finitive radiotherapy, information on total dose, fraction
dose and fractions per week delivered to primary tumor
and N+ neck is collected, as well as total dose, fraction
dose, number of fractions per week, and radiotherapy dur-
ation delivered to elective lymph nodes. For patients
treated with postoperative radiotherapy, information on
total dose, fraction dose, number of fractions per week
and the overall treatment of radiation to the high and
intermediate risk and elective target volumes is collected.
For chemotherapy, information on type of chemother-
apy (induction, concomitant chemoradiation, concomi-
tant bioradiation, postoperative chemotherapy, or other),
used cytostatic agents, chemotherapy scheme, comple-
tion of chemotherapy or reason for non-completion,
start date, final dose (mg/m2), and information on ad-
verse events is collected.
Outcome assessment protocol
Data are collected according to an assessment protocol
(patient reported outcome measures (PROMs) and field-
work) and subsequently stored in the data warehouse.
PROMs target demographic (age, gender, socio-
economic status, marital status, literacy), personal fac-
tors (personality, coping style), HRQOL, psychological
(depression, anxiety, fatigue, pain, sleep, mental adjust-
ment to cancer, posttraumatic stress), physical (speech,
swallowing, physical fitness, neurocognitive function,
sexual function), social (social function, social support,
work, health care use, and costs), and lifestyle (physical
activity, smoking, alcohol, drugs) factors. An overview of
the PROMs is provided in Table 1.
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Table 1 Overview of all NET-QUBIC outcome measures and assessment times
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The interviews target the presence of depression and
anxiety (World Health Organisation (WHO)-Composite
International Diagnostic Interview version (CIDI), Nutri-
tional status (Mini Nutritional Assessment (MNA) and
Dietary intake (24-h recall). Physical tests include assess-
ment of body composition (height, weight, weight loss,
circumferences (waist, hip, and upper arm), and skin-
folds), systolic and diastolic blood pressure, cardiorespi-
ratory fitness (step test), upper (hand grip test) and
lower (chair test) extremity muscle strength, and neuro-
cognitive function (memory: Hopkins Verbal Learning
Test; verbal fluency: Controlled Oral Word Association;
visual-motor scanning speed: Trail Making Test Part A;
executive functioning: Trail Making Test Part B). Ob-
jective levels of physical activity are assessed using an ac-
celerometer (ActiTrainer). Oral function is assessed via
the Functional Rehabilitation Outcome Scale (FROG),
and assessment of trismus and dentures. Digital speech
recordings are made via a standardized procedure enab-
ling speech quality analyses. An overview is provided in
Table 1.
Biobanking
In NET-QUBIC frozen tissue, blood components and
oral rinses are collected at baseline, 6, 12, and 24
months. Formalin-fixed paraffin-embedded biopsies are
routinely available from the pathology archives, but bio-
banking of frozen samples demands collection of extra
biopsies. When patients are surgically treated, the
resected specimen is sampled, but in all other cases add-
itional biopsies are collected. Generally, 1 to 3 biopsies
are taken, depending on the size of the tumor. These
multiple biopsies increase available tissue amounts and
allow studying intratumor heterogeneity. All oropharyn-
geal tumors are tested for HPV virus infection as routine
using p16 immunostaining followed by an HPV DNA
PCR for the p16-immunopositive cases. The tissue biop-
sies are snap frozen and stored in liquid nitrogen.
Oral rinse sampling is performed and saliva sampling
includes four saliva samples per assessment: at the time
of awakening, 30 min post-awakening, 60 min post-
awakening, and at 22:00 h. Afterwards, the subjects are
asked to return the samples by postal mail to the coord-
inating research center. After receipt, salivettes are cen-
trifuged at 2000 g for 10 minutes, aliquoted and stored
at − 20 °C.
Blood samples are obtained to assess parameters of car-
diovascular, main organ function, immune function, and
metabolic syndrome using routine assays. Additional
blood samples are processed in components and stored at
− 80 °C. An EDTA sample is sent to the coordinating cen-
ter and DNA isolated and stored. A PaxGene tube of
blood for RNA profiling is collected and stored at − 20. A
serum sample is collected, centrifuged, the supernatant
aliquoted and stored at − 20 °C. Four additional EDTA
samples are collected and used for isolation and storage of
plasma, blood platelets, cryopreserved Peripheral Blood
Mononuclear Cells and pelleted Polymorphonuclear leu-
kocytes. A Standard Operating Procedure (SOP) forms
the basis to collect, isolate and store these components.
The consented SOP was introduced to the participating
centers and for quality control, samples were isolated at
every center from healthy volunteers, and the sample per-
formance tested at a central laboratory (Amsterdam
UMC) in functional (Antibody-dependent cellular cytoxity
of PBMCs) and molecular assays (all other samples).
Quality control was sparsely budgeted and thus limited,
but revealed that all samples from all centers could be
assayed well. Most variable was the quality and functional
activity of cryopreserved PBMCs as expected, but with
proper experimental controls also these samples are
evaluable.
Data management: planning, collection and storage
Planning
All patients fill out PROMs before treatment and at 3, 6,
12, 24, 36, 48, and 60 months follow-up. Interviews,
physical tests and biological sample collection are
assessed at baseline and 6, 12, and 24months follow-up
only (because of budget restraints) (Fig. 1). The protocol
for caregivers includes blood samples and oral rinse at
baseline and a tailored list of questionnaires, adminis-
tered at the same time points as the patients.
In total, 739 HNC patients and 262 informal caregivers
have been enrolled. Data and sample collection is still
ongoing and will continue to 2023 (60 months follow-
up). Participants are informed about the study progress
by newsletters and the website (kubusproject.nl). There
is prompt and adequate response to any question or let-
ter from the participants. The patient and the general
practitioner are informed on the home test results re-
garding e.g. body mass index, blood pressure or blood
results, and in case of deviant test scores also the attend-
ing head and neck surgeon, radiation oncologist and/or
medical oncologist (for care-givers, only their general
practitioner).
Data collection
Data and sample collection take place at home visits
or at the hospital, and consists of PROMs, an inter-
view and functional tests, and collection of biological
samples. PROMs are sent to the patients by postal
mail. During home visits, neurocognitive tests, phys-
ical tests and a face to face interview take place, and
blood samples are drawn. Tubes to collect saliva, and
the accelerometer are given to the patients after the
home visit. After completion of the measurements,
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patients send the tubes and accelerometer to the re-
searcher by postal mail with the envelope provided.
Patients are allowed not to complete all three compo-
nents (PROMs, interview/tests, biobanking) if this is
too much burden, or for logistic reasons (e.g. time
too short between diagnosis and start of treatment).
Research assistants conduct the field work, and
manage the data collection. All data are coded dir-
ectly after being collected and are entered into the
NET-QUBIC data warehouse to ensure accuracy and
completeness of the data. The field workers are
extensively trained and supervised by a coordinating
research nurse. Data management is coordinated at
the Department of Otolaryngology / Head & Neck
Surgery of Amsterdam UMC location VUmc, and
GGZInGeest in Amsterdam. A special team of data
managers takes care of data quality, data archiving
and the creation of variables and scales. The NET-
QUBIC Data Warehouse makes use of Open Clinica
(collection of multisite case record forms) and Blaise
(face to face data collection). This Data Warehouse is
used to collect and store cancer and treatment data,
outcome, PROMs, results of medical examination and
function tests, and biobank data. Also, the logistics
for project management are structured by means of
this system.
Data storage
Data and samples are stored via FAIR principles: Find-
able, Accessible, Interoperable, Re-usable (www.force11.
org). Findable data: Data are described on the NET-
QUBIC project website (www.kubusproject.nl). Access-
ible data: The collection and integration of large
amounts of personal, biological, genetic and diagnostic
information precludes open access to the NET-QUBIC
research data. In the section Data and sample dissemin-
ation (below) is described how the data are made avail-
able for the research community. Interoperable data: All
data is encoded by a single participant number that
includes an institute code. This allows exchange of all
collected data, but adding new clinical data requires that
the codes at the participating institutes are broken. Re-
Fig. 1 Flowchart of all eligible HNC patients and reasons for non-participation
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usable data: Validated longitudinal data from the 739 pa-
tients and 262 caregivers, as fixed datasets will be avail-
able for re-use. The storage time is 15 years as the legal
minimum for clinical data.
Data and sample dissemination
Data and sample releases will be organized 1 to 2 times
a year and will be announced on the project website
(www.kubusproject.nl). Usage of NET-QUBIC data and/
or biomaterials is regulated in the NET-QUBIC Data
and Biomaterial Access Policy, and in the NET-QUBIC
Publication policy (study procedures available via the
website). In brief, access is provided as follows: A single-
entry portal to all activities is provided on the NET-
QUBIC website. The proposals can be submitted via an
on-line application form. The NET-QUBIC team over-
sees the projects from evaluation, to experiment, to re-
port after completion. Questionnaires are sent to users
(i.e. 1 year following access provision) for feedback on
the access service and to summarize the results (includ-
ing patents and publications), enabling an evaluation of
the outcome of the projects. An applicant will first
choose the type of support and sample/data that they
need for their proposed projects. The forms will be filled
out by the applicant, and submitted to the NET-QUBIC
Access Board for review. Transparency, fairness and im-
partiality are key objectives for the evaluation of the pro-
ject ideas and project applications. Applications are
judged on (i) scientific merit / excellence, and (ii) ex-
pected scientific, societal and economic impact, both
carrying equal weight. While judging research protocols,
there will also be emphasis on overlap between protocols
(e.g. PhD-trajectories) and in case of overlap, researchers
are encouraged to collaborate. Evaluation reports will be
provided for all projects, including those that fail. These
reports will provide constructive feedback from the eval-
uators that will help researchers to improve their pro-
jects. When a research protocol is granted, the data are
made available by a fully automatic procedure by means
of a protected website tool for researchers to download
the requested data. For use of biobank samples, the re-
search methods and requested amounts are critically
reviewed and projects combined whenever possible.
Before biobank samples are released, the research proto-
cols are reviewed by the Institutional Review Board on
Biobanking at the coordinating center. The participating
centers agreed to this approach. Data and samples are
accessible for external parties by collaboration with one
of the Access Board members of the participating
institutes.
A Data Transfer Agreement (DTA) or a Material and
data Transfer Agreement (MTA), all according to na-
tional and European Law and Regulations as the Euro-
pean General Data Protection Regulation (GDPR) will
be signed by the legal representative of the institute of
the researcher and the PI. It also contains an Intellectual
Property Strategy. The Technology Transfer Office in
Amsterdam (IXA) and the legal representatives of the
Board of Directors of all participating institutes have
been actively involved in developing the Research Agree-
ment, the data and biomaterial access and publication
policies, and DTA/MTA. Research data obtained from
new studies (e.g. new biomarkers) will be brought into
the data warehouse for use in future studies.
Study cohort
The flow diagram is shown in Fig. 1. Recruitment took
place from March 2014 to June 2018. During this study
period, in all 8 HNC centers in the Netherlands 9802 pa-
tients were treated for oral cavity, oropharynx, hypo-
pharynx, or larynx cancer, or unknown primary tumors
(the included HNC subsites in NET-QUBIC), of which
5611 in the NET-QUBIC centers (5 out of the 8 HNC
centers). In the 5 NET-QUBIC centers, 2777 patients
were screened for eligibility of which 1861 patients were
eligible and approached for participation (see also Fig. 1)
. Reasons for not asking patients to participate were not
systematically documented, but frequently mentioned
reasons were that a) time between diagnosis and start of
treatment was so short that obtaining informed consent
before treatment was not possible, b) patients were con-
sidered too fragile to participate, or c) recruiters over-
looked patients for participation.
Of the 1861 patients who were asked, 739 patients
were willing to participate (40%). Reasons not to partici-
pate were: feeling psychologically incapable to partici-
pate (n = 539), not wanting to participate (n = 228), no
time (n = 169) and feeling physically incapable to partici-
pate (n = 60); 71 patients provided no reason. In total,
262 informal caregivers agreed to participate. An over-
view of the sociodemographic and clinical characteristics
of the 739 HNC patients and 262 informal caregivers is
provided in Table 2.
To evaluate possible bias in the NET-QUBIC cohort in
relation to the patient cohort in the Netherlands, we ob-
tained data from the Netherlands Cancer Registry (NCR)
on the total Dutch HNC population in all eight HNC cen-
ters, treated from March 2014 to June 2018 in the
Netherlands (the same study period as in the NET-
QUBIC project) for newly diagnosed squamous cell car-
cinomas in the head and neck (oral cavity, oropharynx,
hypopharynx, larynx, unknown primary; all stages); age >
18 years; all treatment modalities (surgery, radiotherapy,
chemotherapy); exclusion criteria were: other tumors in
the head and neck (e.g. lymphoma, skin malignancies, thy-
roid cancer). These are the same in- and exclusion criteria
as in the NET-QUBIC project. The NCR does not have
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data on the NET-QUBIC inclusion criteria “treatment
with curative intent; able to write, read, and speak Dutch”
nor on the exclusion criteria “patients unable to under-
stand the questions or test instructions; severe psychiatric
co-morbidities (i.e. schizophrenia, Korsakoff ’s syndrome,
severe dementia); unable to understand informed con-
sent”. The NCR does not have information either on infor-
mal caregivers of HNC patients. In total, we obtained
overall data (sex, age, HNC subsite, stage, and treatment
modality) on 9802 Dutch HNC patients.
The NET-QUBIC patient cohort (n = 729 (739–10 pa-
tients who did not provide informed consent to combine
their data with other registries)) was compared to the
total Dutch HNC patient population (n = 9073 (9802–
729)) regarding sex, age, tumor subsite and stage, and
treatment modality (Chi-square or t-tests, p < .01 was
Table 2 Overview of the characteristics of the NET-QUBIC population.
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considered as significantly different) (Table 3). The
NET-QUBIC cohort differed significantly from the
Dutch HNC patient population regarding sex (less fe-
males (26% vs. 33%)), age (on average 3 years younger),
tumor subsite (relatively less oral cavity cancer (27% vs.
36%) and more oropharynx cancer (36% vs. 24%)), and
treatment modality (relatively less often surgery (38% vs.
44%), and more often radiotherapy (79% vs. 64%) and
chemotherapy (32% vs 20%). There were no differences
regarding tumor stage (Table 3).
We also compared the NET-QUBIC cohort with the
Dutch HNC population per tumor subsite (oral cavity,
oropharynx, hypopharynx, larynx) regarding sex, age,
tumor stage, and treatment modality (Table 3). The
NET-QUBIC oral cavity group was on average 3.5 years
younger, and more often treated with surgery (93% vs.
79%) and radiotherapy (50% vs. 39%) compared to the
total Dutch oral cavity cancer group. The NET-QUBIC
oropharynx group was on average 2 years younger, less
often treated with surgery (10% vs 17%), more often with
radiotherapy (99% vs 85%), and more often with chemo-
therapy (57% vs 39%). The NET-QUBIC hypopharynx
cancer group was on average 3 years younger, and more
often diagnosed with early stage cancer (23% vs. 10%)
compared to the total Dutch hypopharynx cancer group.
The NET-QUBIC larynx cancer group was, besides on
average 2 years younger, otherwise comparable with the
total Dutch larynx cancer group.
Discussion
Literature suggests that the course of HRQOL and its
association with survival is influenced by various cancer-
related, personal, genetic, biological, psychobehavioural,
physical, lifestyle-related, and social factors, which may
also interact with each other. Many (molecular) mecha-
nisms possibly influencing the course of HRQOL and
the relation between HRQOL and survival are unknown.
There is a strong unmet need for high quality data and
biological sample resources to advance our knowledge.
Besides NET-QUBIC, there are a few other large re-
sources such as national registries (e.g. the United States
National Cancer Institute program [62], the Dutch Head
and Neck Society [5], the Danish Head and Neck Cancer
Group [63]), the data warehouse of the EORTC with
data of international clinical trials (www.eortc.be), and
some other large longitudinal cohort studies in the
United States [64–66], and the Head and Neck 5000
(HN5000) project in the UK [67, 68]. These large re-
sources can be seen as complementary, as they all have
clinical and socio-demographic information, but some
have biological samples and others do not, some have
detailed data on symptoms, lifestyle, and HRQOL in a
relatively smaller (< 1000, e.g. NET-QUBIC) cohort and
others have less detailed data but in a relatively larger
cohort (e.g. the HN5000), all dependent on the purpose
and capacities of these registries and projects.
A strength of NET-QUBIC is that the outcome assess-
ment protocol was developed following the standardized
assessment and evaluation of functioning based on the
International Classification of Functioning, Disability and
Health (ICF) Core Set for HNC (www.icf-core-sets.org),
and the protocol also complies with the HNC toolbox as
described by Ringash et al. [69]. We followed a three step
approach including 1) preselecting instruments for the
Table 3 Differences in demographic and clinical characteristics between the NET-QUBIC HNC patient cohort and the general Dutch
HNC patient population
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assessment of HRQOL and functioning, based on our pre-
vious research targeting HNC patients and other large
scaled cohort studies on ageing (www.lasa.nl) and depres-
sion and anxiety (www.nesda.nl), (2) a pilot study among
15 HNC patients which proved that the outcome assess-
ment protocol is feasible [70], (3) finalizing the outcome
assessment protocol and study procedures including SOPs
and training for the field workers. However, not all
selected outcome measures have undergone thorough
evaluation of all psychometric criteria according to the
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) criteria (www.cos-
min.nl). Another strength is the large longitudinal biobank
that can be applied for tumor-educated blood platelet pro-
filing (already carried out), circulating tumor DNA ana-
lysis (already carried out), and immune profiling, and the
data linked to outcome and HRQoL.
Another strength of NET-QUBIC is that data and sam-
ples are collected according to FAIR principles: Findable,
Accessible, Interoperable, Re-usable. Legal issues are han-
dled through a multicenter research agreement including
MTA/DTA, taking into account the GDPR. There were
several problems encountered before we achieved this
agreement: the laboratory infrastructure had to be set-up
at some centers, and storage of samples to local protocols
required reorganization of the planned biobanking. Also
the procedures on making data and biosamples available
had to be centralized to prevent a huge administration for
the researchers, and this was not in line with the standard
policies at the participating institutes. A consensus could
be reached between all centers, but this required extensive
preparations. These problems caused a delay in starting
recruitment of participants in some centers and took con-
siderable time and efforts of the (local) principal investiga-
tors and legal advisors during the study. A limitation of
NET-QUBIC is the response rate of 40%, which is slightly
lower than the response rate as reported in the HN5000
cohort (49%) [68]. The NET-QUBIC cohort is not com-
pletely representative for the Dutch HNC population re-
garding age (on average 3 years younger), sex (less women
participated), tumor subsite (less patients with oral cavity
cancer and more patients with oropharynx cancer), and
treatment modality. There were no differences regarding
tumor stage.
The NET-QUBIC Datawarehouse and Biobank are
open for collaboration with (inter)national researchers.
Already planned studies include 1) The course of
HRQOL in HNC patients from baseline to 2 years
follow-up, and to identify cancer-related, personal, gen-
etic, biological, psychobehavioural, physical, lifestyle-
related, and social determinants of HRQOL, 2)
Whether the association between HRQOL and survival
is direct or mediated by other variables, 3) The course
of HRQOL in informal caregivers, 4) The course of
symptoms of depression in HNC patients and the rela-
tion with survival, 5) Treatment optimization in elderly
HNC patients, and 6) Predictive models for objectively
and subjectively measured salivary, mastication, and
swallowing function in relation to HRQOL. The first
data release in 2017 granted access to 6 other studies
making use of data of the first 254 included patients.
The second data release in 2019 granted access to 7
new studies making use of all 739 included patients and
262 caregivers at baseline, and at 3 and 6 months
follow-up. In the near future, new data releases will be
organized and will be announced on the website www.
kubusproject.nl.
In conclusion, by granting access to all interested
researchers to the NET-QUBIC data, we enable new re-
search lines in for example: clinical research (e.g. treat-
ment optimization in elderly patients), biological research
(e.g. liquid biopsy analysis for follow up), molecular/digital
pathology based predictive biomarker research, HRQOL
research (e.g. the impact of toxicity on HRQOL), and in-
terrelated research (e.g. prediction of treatment response,
based on clinically validated biomarkers; HRQOL in rela-
tion to biomarkers and survival). Managing this access in
an integrated (inter)national network is crucial to advance
research with broad, multidisciplinary impact.
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